Dermatomyositis Clinical Trial News!

Are you an adult who has been diagnosed with Dermatomyositis (DM) or probable DM? There is a new Phase II study currently recruiting that you may want to discuss with your doctor. It is called PIONEER and the  clinical trial identifier on is: NCTO2612857.

This is a randomized, double–blind, placebo controlled, 24-week trial. That means that neither the participants, nor those running the trial will know who is getting the investigational drug, and who is getting a placebo. Your participation will help move the science of treating DM forward, but remember, you may or may not be actually receiving the investigational drug.

The potential risks and benefits will be explained to you before you sign a consent form, if you meet all the qualifying criteria for participation. There are about 22 centers who are administering this trial in the US, and in Europe.

You can find out more by clicking here.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email